- Home
- ZBH vs RPRX Comparison
ZBH vs RPRX Comparison
Compare ZBH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBH
- RPRX
- Stock Information
- Founded
- ZBH 1927
- RPRX 1996
- Country
- ZBH United States
- RPRX United States
- Employees
- ZBH N/A
- RPRX N/A
- Industry
- ZBH Industrial Specialties
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZBH Health Care
- RPRX Health Care
- Exchange
- ZBH Nasdaq
- RPRX Nasdaq
- Market Cap
- ZBH 19.9B
- RPRX 16.2B
- IPO Year
- ZBH N/A
- RPRX 2020
- Fundamental
- Price
- ZBH $88.48
- RPRX $38.74
- Analyst Decision
- ZBH Buy
- RPRX Strong Buy
- Analyst Count
- ZBH 19
- RPRX 3
- Target Price
- ZBH $108.56
- RPRX $46.00
- AVG Volume (30 Days)
- ZBH 2.2M
- RPRX 3.5M
- Earning Date
- ZBH 11-05-2025
- RPRX 11-05-2025
- Dividend Yield
- ZBH 1.08%
- RPRX 2.28%
- EPS Growth
- ZBH N/A
- RPRX N/A
- EPS
- ZBH 4.03
- RPRX 1.75
- Revenue
- ZBH $8,010,900,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- ZBH $8.20
- RPRX $36.16
- Revenue Next Year
- ZBH $5.92
- RPRX $2.04
- P/E Ratio
- ZBH $22.00
- RPRX $22.00
- Revenue Growth
- ZBH 5.47
- RPRX 3.70
- 52 Week Low
- ZBH $85.33
- RPRX $24.05
- 52 Week High
- ZBH $114.72
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- ZBH 31.07
- RPRX 57.20
- Support Level
- ZBH $85.33
- RPRX $38.39
- Resistance Level
- ZBH $90.16
- RPRX $41.24
- Average True Range (ATR)
- ZBH 2.96
- RPRX 1.16
- MACD
- ZBH -1.60
- RPRX 0.21
- Stochastic Oscillator
- ZBH 14.01
- RPRX 50.33
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.